Blood test could predict which melanoma patients benefit from immunotherapy
NCT ID NCT05105100
Summary
This research study aimed to understand how immune cells in the blood might predict whether melanoma patients respond to pembrolizumab immunotherapy. Researchers followed 25 patients with advanced melanoma who were starting standard pembrolizumab treatment. They analyzed blood samples to identify patterns in immune cells that could indicate whether the treatment would work or if resistance might develop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.